History of tumour vaccines
Vaccination has become standard procedure for the prevention of numerous infectious diseases. The application of vaccines to other diseases, such as cancer, is now possible owing to advances in molecular engineering and a better understanding of tumour immunology. The concept of vaccines for cancer treatment is not new and was suggested nearly 100 years ago, when William Coley reported that inoperable sarcomas underwent regression after patients developed erysipelas, a severe bacterial skin infection (Ref. 1) . Over the years, many attempts have been made to generate effective cancer 'vaccines' from mixtures of tumour cells and infectious particles (so-called Coley's toxins) without much success. During this time, studies of transplantable tumours in animals established the feasibility of tumour rejection through immune-mediated mechanisms. These studies suggested that tumour cells expressed unique antigens (i.e. antigens that were not found on normal cells). These antigens, under appropriate conditions, could be recognised by components of the immune system. Further research identified many of the antigens that induced tumour rejection as normal self-proteins. There are many reasons why self-proteins might be recognised by the immune system, including the presence of mutations in the coding regions of the protein, unusually high levels of the protein, and abnormal patterns of glycosylation of the protein. The awareness that T lymphocytes (T cells) are significant mediators of tumour rejection has focused attention on the isolation of antigens that are specifically recognised by T cells. T cells recognise antigens as smaller fragments of proteins, so-called epitopes, only after their intracellular degradation and presentation on the cell surface, where they are bound to the major histocompatibility complex [MHC, or human leukocyte antigen (HLA) in humans]. The first T-cell-specific tumour antigen was derived from malignant melanoma cells; subsequently, many other tumour antigens in a variety of tumours have been found to possess T-cell-specific epitopes.
History of CEA
CEA was one of the first tumour-associated antigens to be identified and has been well characterised. CEA is an oncofetal glycoprotein, which is found at high levels in the fetal colon and at lower levels in the normal adult colonic epithelium. CEA occurs at abnormally high levels in several benign disorders and in some malignant tumours, including those of the stomach, small intestine, colon, rectum, pancreas, liver, breast, ovary, cervix and lung (Refs 2, 3). Recently, several T-cell epitopes within CEA that are recognised by human T cells have been described (Refs 4, 5, 6) . Several different strategies are now using vaccination to target CEA, and clinical trials have started to yield interesting findings. In this review, we have discussed the rationale for using CEA as a target for vaccination, some of the various strategies for enhancing vaccination against CEA, and some of the problems that need to be solved before CEA vaccines can be considered standard therapy. The current status of clinical trials and new animal models have also been reviewed. Although more research is necessary, successful vaccination against CEA could affect many individuals who have cancer and even more individuals who are at risk of developing cancer. Thus far, CEA appears to be a promising antigen for vaccine therapy; however, further studies are required to define the best strategy for the clinical application of CEA-directed vaccines.
Biology of CEA
CEA is a 180-kD glycoprotein that occurs at high levels in colon epithelial cells during embryonic development. Levels of CEA are significantly lower in colon tissue of adults, but can become elevated when inflammation or tumours arise in any endodermal tissue, including in the gastrointestinal tract, respiratory tract, pancreas and breast. CEA was originally isolated from a colon carcinoma specimen in 1965 (Ref. 7) . The construction of monoclonal antibodies against CEA allowed the detection of the overexpression of CEA protein in a variety of adenocarcinomas, including gastric, pancreatic, small intestine, colon, rectal, ovarian, breast, cervical and nonsmall-cell lung cancers (Refs 2, 3). Currently, 500 000 individuals are diagnosed with CEAproducing tumours each year in the USA alone (Ref. 8) . CEA is also expressed by epithelial cells in several non-malignant disorders, including diverticulitis, pancreatitis, inflammatory bowel disease, cirrhosis, hepatitis, bronchitis and renal failure and also in individuals who smoke (Ref. 9) . This fact has made it difficult to use serum CEA determination as a sensitive method for cancer screening. However, serum CEA levels have been useful in monitoring individuals for the recurrence of cancer (Ref. 10 ).
In 1986, the gene that encodes human CEA was localised to chromosome 19, and subsequently cloned (Ref. 11) . In humans, the CEA gene encodes a messenger RNA (mRNA) that is 3100 base pairs long and translates to a protein that has a molecular weight of 70 kD. The additional weight of the protein is provided by an extensive pattern of carbohydrates that are added by glycosylation enzymes, leading to a final weight of 180 kD. The structure of CEA protein includes an N-terminal sequence followed by three disulphide-linked repeats of 178 amino acids, and a hydrophobic C-terminal domain (Fig. 1) . This structure is similar to that of the immunoglobulins, and has established CEA as a member of the superfamily of immunoglobulin genes (Ref. 12) . A unique feature of CEA is that it is linked via lipid into the membrane, through a glycosylphosphatidylinositol moiety, making it distinct from other members of the CEA family (Ref. 13) . Several other antigens are closely related to CEA, including the non-specific cross-reacting antigen (NCA), biliary-specific glycoprotein (BGP), CEA gene family member CGM-6 and pregnancy-specific glycoproteins (Ref. 14) . Some of these represent separate species, whereas others may be splice variants of CEA. Currently, 29 separate genes have been identified as coding a CEA-related gene product, and most of these genes are located on the long arm of chromosome 19 (Refs 15, 16, 17) .
The function of CEA in normal colon epithelial cells and in tumour cells is not entirely clear. Many members of the immunoglobulin gene family serve as recognition markers, and this might be true for CEA as well. Studies have reported that CEA localised on the cell surface of colon tumours and other cells can act as a homotypic adhesion molecule, resulting in the aggregation of CEA-expressing cells (Ref. 18) . Furthermore, although CEA is produced at low levels in normal colonic epithelial cells in adults, the pattern of localisation differs from that observed in most colon tumour cells or in the developing embryonic colon. In normal colonocytes, CEA is localised only at the luminal surface of the cells, whereas in tumour cells, it is found in a disordered pattern throughout the cell membrane (Ref. 18 ). Thus, current models suggest that CEA promotes the spatial orientation of colon epithelial cells to one another and to the surrounding matrix during embryonic development of the colon, and helps maintain the integrity of the luminal epithelium in the adult colon. The altered pattern of localisation in tumour cells may help to disrupt the intercellular adhesion of colonocytes, resulting in the disorganised growth and movement of malignant cells. CEA may also be involved in the enhancement of metastatic disease. Elevated levels of CEA in the serum have been shown to correlate with an increased incidence of liver metastases, and this may be due to adhesion between circulating CEA in the liver and CEA bound to metastatic tumour cells (Ref. 19) . This may explain the high incidence of hepatic metastases in those patients who have primary tumours that express CEA.
Several different lines of investigation have suggested the possibility that CEA can serve as an antigenic target for eliciting anti-cancer immune responses. Adaptive immune responses to any antigen can be broadly characterised by the production of specific antibodies (i.e. humoral immunity) or the generation of antigen-specific T cells (i.e. cellular immunity). Shortly after the discovery of CEA protein, several groups sought to determine whether individuals who had colon cancer developed anti-CEA antibodies during the course of their disease (Refs 20, 21). Some groups did not find significantly elevated titres of such antibodies; however, others did find evidence that antibody responses to CEA occurred in some individuals. The reasons for this discrepancy might relate to the presence of circulating antigen-antibody complexes, making it difficult to detect the antibodies, especially using the technology that was available at the time (Ref. 22) . The potential for CEA to elicit T-cell responses was first suggested by the observation that individuals who had colon cancer often exhibited a delayed-type hypersensitivity (DTH) response to purified CEA protein (Ref. 23 ). More recently, recombinant vaccinia viruses expressing CEA were administered to cancer patients, and CEA-specific T cells were subsequently cloned from these patients, demonstrating that T cells can recognise CEA (Ref. 4) . Several independent groups have now reported the existence of multiple epitopes within CEA that are recognised by human T cells that bind to various HLA class I molecules (Refs 4, 5, 6).
Strategies for CEA cancer vaccine development
Two lines of evidence have supported the use of CEA as a target for vaccine development: The CEA protein product contains a leader sequence and three highly conserved repeat domains (1-3), each comprising 178 amino acids. Each of these three repeat domains can be further divided into two sub-domains (A and B), which share significant sequence homology. Each domain contains four cysteine residues at similar positions, which pair up to form A and B 'loops' stabilised by disulphide bridges between the cysteines. (a) The domains and sub-domains in the CEA gene correspond to the labelled domains of the mature protein shown in (b). The CEA protein consists of 668 amino acids, and has a configuration that is similar to that of other members of the immunoglobulin gene superfamily. The protein extends out from the cell membrane into the extracellular space, and is anchored through a hydrophobic C-terminal region (the M domain; Ref. 
Monoclonal-antibody therapy
Monoclonal antibodies directed against CEA were initially used for diagnostic purposes, including the immunohistochemical staining of tissue specimens and the localisation of disease in vivo. The coupling of a radioactive isotope to the antibody greatly enhanced the effectiveness of using monoclonal antibodies for detecting potential sites of disease (Ref. 26) . The use of antibody-targeted therapeutics for cancer treatment has shown that tumour-cell lysis can be initiated by immune-mediated mechanisms. Antibodies can also be used for the direct delivery of cytotoxic molecules such as radionuclides, toxins or chemotherapy agents to the site of an established tumour.
Unconjugated antibodies
The discovery that anti-CEA antibodies can be used to detect CEA-expressing tumour cells hinted that they could also be used to mediate the rejection of tumour cells through immune mechanisms. When anti-CEA antibodies bind to the surface of a tumour cell, several pathways are activated, which can result in the destruction of an antibody-marked cell (Fig. 2) . 
Antibody conjugates
Another method of using monoclonal antibodies for cancer therapy is to conjugate them to a radionuclide, which can deliver damaging radiation to the vicinity of the tumour (Ref. 32 ).
The advantage of this approach is that targeting a single cell expressing CEA can also lead to the death of nearby tumour cells that are not expressing CEA, owing to a by-stander effect. A similar approach can be used to deliver chemotherapeutic drugs that are known to be toxic to the tumour cells. This is accomplished by conjugating the chemotherapeutic drug to the anti-CEA antibody. 
CEA-derived peptides
T cells appear to play a major role in tumour rejection after vaccination. Antibodies recognise their antigens by the three-dimensional structure of a single antigenic determinant, the so-called epitope. However, T cells recognise antigen only after the antigen has been processed into smaller linear peptide fragments, which are also known as epitopes. These epitopes are loaded onto specific molecules called major histocompatibility complex ( 
Identification of CEA epitopes
Several experimental approaches have been used to identify CEA epitopes that are presented by MHC class I molecules to CD8 + T cells. Thus far, the most commonly used approach has been the identification of a putative peptide sequence by using a computer to predict binding affinity to specific MHC class I molecules. This is now easy because the amino acid sequence of the CEA protein has been determined and all nine potential amino acid sequences can be quickly modelled. The peptide groove of an MHC class I molecule normally binds short peptide fragments that comprise 8-10 amino acids, and because the threedimensional structure of several MHC molecules is known, the computer models can predict the potential peptides that would be expected to bind with high affinity (Ref. 36 ). These peptides can be synthesised and tested in vitro for their actual binding affinity for the MHC molecule and for recognition by specific CTLs (Refs 37, 38, 39).
The above-described method was used to isolate the first HLA-restricted CEA peptide, namely carcinoembryonic-antigen-associated peptide 1 (CAP-1). CAP-1 peptide binds to the HLA-A2 complex, and has been used to generate T-cell lines (i.e. a mixed T-cell population that responds to CEA) from cancer patients who have been vaccinated with recombinant vaccinia virus expressing CEA (Ref. 4) . A T-cell clone (i.e. a single, genetically identical T-cell population that recognises CEA) derived from one of these patients has been shown to lyse target cells that contain CAP-1 and the HLA-A2 complex. To date, several CEA peptides that specifically bind to known HLA molecules have been identified and have elicited T-cell responses (Table 1) . In theory, these peptides can be used to immunise individuals who express the same HLA molecule.
Until recently, CD4 + T cells have received far less attention in tumour immunology. This is due, in part, to less being known about MHC class II structures, and to the fact that most tumour cells do not express MHC class II molecules. However, increasing knowledge about the role of CD4 
Modified CEA peptides
CEA is a self-antigen and is generally considered to be weakly immunogenic. One reason for this might be that CEA peptides bind to MHC molecules or TCRs with low affinity, thus decreasing peptide recognition by T cells. One method for enhancing recognition is to alter the affinity of the peptide for MHC molecules or TCRs by amino acid substitutions of peptide anchor residues or non-anchor residues, respectively (Fig. 4) . This strategy can be applied to any known peptide epitope and may be particularly helpful for increasing the immunogenicity of self-antigens. Modifications in the anchor binding residues have resulted in higher affinity binding and better T-cell responses for several melanoma antigens (Ref. 45) . The CEA peptide CAP-1 was modified by replacing an asparagine residue (N) expert reviews in molecular medicine 48) . In another clinical trial, patients who had colorectal carcinoma were immunised using either recombinant baculovirus containing human CEA alone or in combination with the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF; see later section entitled 'Cytokines'). All six of the patients who received the combination treatment showed early CEA-specific T-cell proliferation after immunisation, whereas only two of the six patients who were immunised with recombinant baculovirus containing CEA without GM-CSF developed an anti-CEA T-cell response after multiple vaccinations (Ref. 49 ). These studies provide good evidence for the use of recombinant CEA protein as a boost following primary viral immunisation, or for its use in combination with immune-stimulatory cytokines.
DNA vaccines
DNA vaccines consist of a bacterial plasmid that contains genes (e.g. pathogens, allergens or Strategies for cancer therapy using carcinoembryonic antigen vaccines 10 expert reviews in molecular medicine A plasmid that encoded the full-length human CEA has been tested by injecting it intramuscularly into mice; both CEA-specific humoral and cell-mediated immune responses were induced. This DNA vaccine also protected mice from a challenge with CEA-expressing colon tumours (Ref. 53 ). The application of DNA vaccines in humans raises several concerns; one of these concerns is the potential for such vaccines to induce anti-DNA antibodies, as observed in patients who have systemic lupus erythematosus (SLE). However, animal studies have shown that vaccination with purified DNA does not induce anti-DNA antibodies (Ref. 54) . Clinical trials using CEA-encoded DNA vaccines are currently in progress and await further evaluation.
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Dendritic cells
Dendritic cells are the most potent APCs and present antigen via the MHC class I and MHC class II pathways. The use of dendritic cells that have been pulsed (i.e. exposed for a short time to high concentrations) with specific antigens has been proposed as a means of generating moreeffective antigen-specific T-cell responses (Ref. 55 ). The identification of several dendritic-cell growth factors, such as GM-CSF and interleukin 4 (IL-4), has permitted their in vitro expansion and activation (Refs 56, 57, 58). Populations of dendritic cells from individual patients (autologous dendritic cells) can be generated using isolated monocytes from peripheral blood; these cells can be expanded ex vivo, pulsed with an antigen and then re-administered to the same patient as a dendritic-cell vaccine. Various strategies for pulsing dendritic cells have been proposed, including the use of MHC-restricted peptides, DNA, RNA, recombinant viruses and tumour-cell lysates. In a Phase I study, patients who had advanced malignancies expressing CEA were vaccinated with dendritic cells that had been pulsed with the CEA peptide CAP-1. A minor clinical response was observed for one of the patients in the study, and disease progression was stabilised in another (i.e. there was no tumour growth following vaccination). No treatmentrelated toxicities were observed, demonstrating the feasibility and safety of this treatment method (Ref. 59 ). Dendritic cells that had been pulsed with a cocktail of melanoma peptides or a tumour lysate were used to treat patients who had advanced melanoma by injecting the cells into or near lymph nodes. Five patients out of 16 produced a clinical response to the vaccine, and two of the five responded completely (Ref. 60) .
Another interesting approach used CEAspecific mRNA and total RNA derived from CEA-expressing tumour cells. The advantage of using CEA-specific mRNA is that RNA encodes multiple CEA epitopes for various HLA types; thus, patients can be immunised without the need for prior identification of their HLA type or the use of HLA-specific CEA epitope(s). Moreover, RNA can be extracted from very small amounts of tumour tissue and encodes the individual array of tumour antigens for that tumour. Studies that utilised autologous dendritic cells that had been pulsed with either CEA peptides or CEA RNA to stimulate isolated T cells from carcinoma patients and healthy donors showed that a CEA-specific CTL response could be elicited in vitro (Refs 25, 61, 62). Another method of generating immunogenic vaccines is to fuse whole tumour cells directly to dendritic cells, using an electrofusion technique. In a pilot study involving patients who had renal cell carcinoma, the administration of a fusion vaccine composed of autologous renal cell carcinoma cells fused to allogeneic dendritic cells produced a significant clinical response in seven of the 17 treated patients, four of which showed complete responses (Ref. 63 ). 12 expert reviews in molecular medicine
Strategies for cancer therapy using carcinoembryonic antigen vaccines
Bacterial vaccines
The delivery of DNA that encodes tumour antigens to APCs can also be accomplished using live attenuated bacteria. The advantages of using bacteria as expression vectors for foreign antigens include improved antigen presentation, because some bacteria are engulfed (taken up) by phagosomes, resulting in the presentation of inserted antigens by both MHC class I and class II pathways. Bacteria also provide the requisite transcriptional and translational machinery for the expression of foreign genes. This may not be true for some viruses that depend on host-cell transcription factors [e.g. retroviruses (lentivirus)] or translation factors [e.g. poxviruses (vaccinia virus)]. In bacteria, post-translational glycosylation of encoded proteins might be problematic. However, as most vaccines aim to elicit a T-cell response that is dependent on the MHC class I or class II pathway, the presentation of peptides should not be restricted. Another advantage of bacterial vectors is that they are sensitive to antibiotics and can be more easily controlled after administration to patients. Animal studies have shown the therapeutic effectiveness of using recombinant bacterial vaccines for the treatment of model tumours; both CD4 + -and CD8 + -antigen-specific T-cell responses were generated (Ref. 
Recombinant viruses
Perhaps the best-studied vaccine development method involves the use of recombinant viruses. The most characterised viral system is that of the poxviruses, particularly vaccinia virus. Recombinant vaccinia viruses can accept a large insert of foreign DNA, replicate accurately, are easily engineered, allow posttranslational modification of foreign proteins (e.g. glycosylation), stimulate strong immune responses, and have been extensively used in the human population to prevent smallpox (Refs 75, 76). The methods for constructing recombinant vaccinia viruses have been well described, and several different tumour antigens have now been placed into these viruses, including CEA (Refs 77, 78).
In a colon carcinoma model in mice, vaccinia virus expressing CEA was found to be effective in treating established CEA-expressing tumours, and was associated with the development of anti-CEA antibody titres and T-cell responses (Ref. 79 ). Interestingly, the vaccine was most effective in preventing the growth of CEA-bearing tumours in pre-immunised animals. The same vaccine has also been tested for safety and immunogenicity in a non-human primate model; toxicity was found to be minimal and the monkeys produced CEA-specific T-cell responses after vaccination (Ref. 80) .
Several clinical trials using recombinant vaccinia vaccine containing the CEA gene to treat patients who had advanced CEA-expressing tumours have provided evidence that vaccination was safe even when high titres of virus were given; CEA-specific T-cell growth and cytotoxicity were also induced (Refs 4, 81). These early clinical trials were designed to determine the safety of vaccination and not to detect clinical responses. All of the patients who were treated had advanced metastatic tumours; furthermore, they had all been vaccinated with smallpox (vaccinia). This would be expected to reduce the chances of an Strategies for cancer therapy using carcinoembryonic antigen vaccines 13 expert reviews The safety of viral vaccines and the ability to generate CEA-specific T-cell responses has led to several novel approaches for improving the clinical effectiveness of the vaccines. This includes the addition of adjuvants, such as cytokines and co-stimulatory molecules (see later sections entitled 'Cytokines' and 'Co-stimulation of tumour-antigen-specific T cells'), to the treatment regimen, and combining different viruses in a 'prime and boost' strategy.
Strategies for enhancing CEA cancer vaccines
Several approaches for vaccine design have been presented; however, the results from clinical trials have thus far been disappointing. One reason might be the use of vaccines in patients who have advanced disease, because they are less likely to elicit a measurable and protective immune response. Although such individuals may be able to respond to common antigens (e.g. influenza or tetanus), their response may be locally immunosuppressed at the tumour site. Thus, patients who have advanced cancers may be less likely to respond to vaccination against a tumour-associated antigen. Several strategies could be employed to improve the ability of CEA vaccines to induce immune responses, as outlined below.
Cytokines
Cytokines are a large family of pleiotropic (i.e. they can act on many different cell types) immune regulatory proteins that are broadly involved in cell growth and differentiation. The release of cytokines by activated T lymphocytes can regulate the type and extent of an immune response that occurs after vaccination; thus, cytokines have been extensively studied for their ability to help induce anti-tumour immunity. IL-2 was the first cytokine to be shown to induce tumour regression in an animal model (Ref. 87). IL-2 has been tested against a variety of human cancers, and has been shown to have therapeutic potential when administered intravenously as a single agent for metastatic melanoma and renal cell carcinoma.
Complete responses have been observed in 7-10% of patients who had either metastatic melanoma or renal cell carcinoma, and an additional 8-10% of the patients exhibited an objective partial response (Ref. 88) . This response rate is modest, but the responses are often quite durable, making IL-2 the treatment of choice for many such patients. The mechanism of tumour rejection associated with IL-2 in patients is still controversial, but probably depends on the expansion of tumourspecific T cells. Because vaccines can induce T-cell responses, it seems logical that IL-2 could be used to amplify the initial response, improving the therapeutic effects of cancer vaccines. This has been confirmed experimentally in a mouse model, whereby IL-2 significantly augmented the antitumour responses of a vaccinia virus expressing CEA (Ref. 89) . A clinical response rate of 42% has been demonstrated in patients who had metastatic melanoma following treatment with a modified melanoma peptide in incomplete Freund's adjuvant and systemic IL-2. These patients experienced an objective cancer regression of their metastases in the brain, lung, liver, lymph nodes and skin (Ref. 90 ). Future studies, using a combination of systemic IL-2 with various forms of CEA vaccines, are necessary to see if similar Strategies for cancer therapy using carcinoembryonic antigen vaccines 14 expert reviews in molecular medicine improved clinical responses can be documented for patients who have CEA-expressing tumours.
Recombinant viral vaccines that encode both tumour antigen and cytokine genes have been constructed. These have been designed to induce the local release of cytokine at the site of T-cell activation, and should limit the systemic toxicity usually induced by the intravenous administration of high doses of IL-2. As a preliminary test of this system, the LacZ gene, which encodes β-galactosidase (an enzyme), was used as model tumour antigen. In a mouse model, the co-expression of LacZ and IL-2 in vaccinia virus enhanced the treatment of β-galactosidaseexpressing pulmonary metastases and increased β-galactosidase-specific CTL responses (Ref. 
Co-stimulation of tumour-antigen-specific T cells
The activation of antigen-specific T cells, leading to cytokine production and proliferation, requires two separate signals (Ref. 95) . The first signal is delivered to the T-cell receptor upon recognition of the peptide-MHC complex. The second signal can be delivered by CD28 molecules expressed on T cells after the engagement of the B7 costimulatory molecule expressed by activated APCs (Fig. 5) 
B7 co-stimulatory molecules
The B7 co-stimulatory molecules are homodimeric (i.e. express two identical, intertwined chains of the same protein) members of the immunoglobulin supergene family; they are found on the surface of cells that are capable of stimulating T-cell activation and proliferation. B7 molecules can bind to either CD28 or CTLA-4 on the surface of T cells. In the first instance, the ligation of CD28 (e.g. via B7 molecules or anti-CD28 monoclonal antibody) delivers an activating signal to the T cell, which induces the release of cytokines. After activation, T cells upregulate the expression of CTLA-4 on their cell surface, which also binds B7 molecules but delivers a negative signal, rendering the T cells less sensitive to further stimulation. The fate of T cells that respond to an antigenic stimulus depends on the balance between the stimulatory and inhibitory signals delivered to the T cell via these surface receptors. Likewise, T-cell activation can be enhanced by selectively stimulating CD28 or blocking CTLA-4 activity, and it can be inhibited by the reverse treatments (Ref. 99) . The expression of B7 molecules on melanoma cells was found to elicit tumour rejection in mice; the antitumour response was mediated by CD8 + T cells (Ref. 100) .
Using a mouse model, a mixture of vaccinia viruses expressing CEA and B7 molecules resulted in enhanced CEA-specific CTL responses and more-effective anti-tumour activity (Ref. 101) . A clinical trial using an ALVAC virus expressing CEA and B7 molecules has been conducted on patients who have advanced CEA-expressing tumours. Eighteen patients were treated with monthly intramuscular injections; no significant side-effects were noted, including any evidence Strategies for cancer therapy using carcinoembryonic antigen vaccines 15 expert reviews in molecular medicine of autoimmune phenomena. Three patients experienced stabilisation of their disease, and this was associated with an increase in CEA-specific T-cell precursors, as measured by in vitro T-cell assays (H. Hörig and colleagues, in prep.). These findings support the use of B7 molecules as a vaccine adjuvant, and suggest that this approach will be safe and might be expected to elicit more-objective clinical responses in larger clinical trials involving patients whose disease is at an earlier stage.
CD40-CD40 ligand co-stimulatory molecules
Interactions between CD40 and CD40 ligand (also known as CD40L or CD154) represent another co-stimulatory system that has been widely studied (Fig. 6) . The CD40 receptor is a 48-kDa protein, which is found on many cell types, especially APCs, such as B cells, dendritic cells, macrophages, monocytes, fibroblasts and endothelial cells. CD40L is a 39-kDa protein that belongs to the TNF family and is predominantly 
Future challenges for CEA vaccine development
Animal models
The major goal of CEA-targeted immunotherapy is to be able to eradicate tumours but minimise damage to tissues that normally express CEA. As discussed, an increasing number of CEA vaccine strategies and host factors can influence the immune response to CEA. Much of our current understanding of CEA vaccine therapy stems from studies of immune-competent mice that have been transplanted with murine tumours that have been transfected with the human CEA gene. Although this model has been useful for comparing various treatment approaches, its direct biological relevance to humans is limited. These models are inadequate to address the issues of pre-existing tolerance (i.e. non-responsiveness) to self-tumour antigens in individuals who have cancer, or the potential for the development of autoimmunity after CEA vaccination. It would be valuable to assess these issues before these vaccines are applied in humans.
Transgenic mice that express the human CEA gene have been generated and represent one potentially useful pre-clinical model for evaluating the full potential of CEA vaccine strategies. These mice express CEA in a spatiotemporal pattern that approximates that of normal CEA expression in humans, and can be used to determine the possible negative side-effects of immunotherapy, including autoimmunity (Ref. 104) . In one study, CEA transgenic mice were subcutaneously transplanted with a mouse colon tumour expressing human CEA. The transgenic mice showed a faster tumour growth rate and were not able to develop anti-CEA antibodies, as compared with non-transgenic mice bearing a CEA-expressing tumour (Ref. 105 ). These studies suggest that tolerance against CEA can occur in an animal model and may represent a better model to assess strategies for vaccinating against CEA. In fact, a vaccinia virus expressing CEA could be used to break tolerance and improve therapeutic anti-tumour responses in CEA transgenic mice (Ref. 106 ).
Routes of administration
Animal models suggest that the route of administration may be an important issue for cancer vaccines. The comparative effectiveness of immunisation with a recombinant vaccinia virus expressing LacZ via the intravenous, subcutaneous or intradermal routes has been studied in mice. A significantly greater reduction in both the size and number of pulmonary metastasis occurred with intravenous immunisation (Ref. 107) . The route of vaccination may also affect the type of immune response. DNA vaccinations given to mice through the intramuscular route resulted in the induction of different classes of T cells and antibodies against a model antigen CD40 on the APC does not bind to CD40L on the T-helper cell, the APC will not be able to prime CD8 + T cells to recognise CEA. T cells will not be able to attack CEA + tumours and can continue to grow unchecked by the immune system. The role of B7 and CD28 is also very important in delivering secondary signals but has been omitted from this diagram for the sake of clarity (see Fig. 5 ). The roles and expression of CD40L in CD8 + T cells are less well understood than those in CD4 + T cells and have also been omitted here. Both CD40 and CD40L are candidates for inclusion in CEA-based cancer vaccines, with the aim to increase priming of APCs and CD8 + T cells for anti-CEA tumourcell killing (fig006hka).
Strategies for cancer therapy using carcinoembryonic antigen vaccines 18 expert reviews in molecular medicine than those induced by the same gene delivered through the intradermal route (Ref. 108) . Recently, intrarectal immunisation using vaccinia virus expressing the HIV gp160 antigen enhanced systemic immunity in vaccinia-primed mice, whereas no augmentation was seen after intravenous immunisation (Ref. 109) .
Several routes and methods of immunisation have been used for vaccination and these can have a significant effect on the type and strength of antitumour immunity. Vaccines can be administered systemically via subcutaneous, intradermal, intramuscular, intravenous, intratumoural, intralymphatic and intraperitoneal injection. Alternatively, they may be given through mucosal application, including intranasal, oral and rectal routes. However, to date, no randomised clinical trials have addressed the issue of which routes are better for the administration of cancer vaccines.
Prime and boost strategies
The generation of multiple vectors for vaccination, and the development of neutralising antibodies that prevent repetitive exposure to a single vector, has led to the use of prime and boost strategies. Such protocols prime the immune response with one vector expressing an antigen, and then boost with a different vector expressing the same antigen. Heterologous boosting of mice using first vaccinia virus and then ALVAC virus expressing CEA improved tumour responses and CTL activity against CEA, compared to those produced by vaccination with either virus alone (Ref. 110) . Clinical trials are beginning to suggest similar results. In one study, vaccinia and ALVAC viruses expressing CEA were administered alternately; the highest levels of CEA-specific precursor T cells were generated by the group of patients who were primed with vaccinia-CEA vaccine before being given ALVAC-CEA vaccine (Ref. 
Research in progress and unanswered questions
CEA was one of the first tumour antigens to be isolated from cancer patients and is expressed on many different types of tumours. The molecular biology of CEA has been extensively studied and the gene that encodes it has been cloned. Less is known about the immune responses to CEA in cancer patients, although studies have suggested the generation of both antibodies and T-cell responses are possible. The identification of T-cell epitopes within CEA led to the development of numerous recombinant and synthetic vaccine strategies for immunisation. These strategies include the use of CEA peptides, recombinant CEA protein, recombinant bacteria and viruses expressing CEA, CEA-pulsed dendritic cells and anti-CEA monoclonal antibodies. A better understanding of how immune responses are generated has resulted in the addition of cytokines and co-stimulatory molecules as adjuvants to CEA-directed vaccines. These strategies have improved the induction of immune responses to CEA in animal models and, in some cases, in patients treated in early-phase clinical trials. Current problems include the lack of an adequate animal model and limited knowledge about the optimal routes of administration and dosing schedule for vaccination. The early clinical trials suggest that vaccination with CEA vaccines is safe, producing few side-effects, and can lead to CEAspecific immunity. Additional research to define the best approach to vaccination and intervention at earlier stages of disease will further improve the effectiveness of vaccine therapy. CEA remains a useful target for the development of vaccines for the treatment and prevention of cancer.
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